Two Strategies for Methicillin-resistant Staphylococcus Aureus (MRSA) Infection Prevention in Surgical Patients (MOSAR-04)

This study has been completed.
Sponsor:
Collaborator:
European Commission
Information provided by (Responsible Party):
Stephen Harbarth, University Hospital, Geneva
ClinicalTrials.gov Identifier:
NCT00685867
First received: May 27, 2008
Last updated: August 20, 2012
Last verified: August 2012
  Purpose

The study is a two-arm controlled multi-centre trial of two strategies to reduce nosocomial MRSA transmission and infection among surgical patients. Enrolment and primary analyses will be performed at the hospital level. A total of ten adult surgical departments with at least 3 surgical subspecialties each will participate in the study. Sites of the study are located in 9 countries (UK, France, Spain, Germany, Switzerland, Italy, Serbia, Greece and Israel).

The primary objective is to determine the effect of an early MRSA detection & decolonization & isolation strategy compared to an enhanced standard control strategy on healthcare-associated MRSA isolation rates among surgical patients at risk of MRSA carriage, who are hospitalized for at least 24 hours.


Condition Intervention
MRSA Infection
Other: Rapid molecular MRSA test
Behavioral: Hand hygiene promotion

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: An Interventional Study to Evaluate the Impact of Two Innovative Strategies in Preventing Nosocomial MRSA Infection in Surgical Patients

Resource links provided by NLM:


Further study details as provided by University Hospital, Geneva:

Primary Outcome Measures:
  • Nosocomial MRSA isolation rate (expressed as the monthly rate of MRSA in clinical isolates divided by the number of susceptible patients per hundred) [ Time Frame: Monthly ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Nosocomial MRSA infection rate (= number of nosocomial MRSA infections per 100 admissions) [ Time Frame: Monthly ] [ Designated as safety issue: No ]

Enrollment: 126750
Study Start Date: May 2008
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Rapid detection
Other: Rapid molecular MRSA test
PCR-based rapid screening for MRSA carriage
2
Enhanced infection control
Behavioral: Hand hygiene promotion
  • Promotion and monitoring of hand hygiene, with special emphasis on alcohol-based hand rubs and feedback of hand hygiene compliance
  • Standard precautions (e.g. use of gloves for contacts with wounds and body fluids)
  • Isolation precautions according to the hospitals' capacity and strategy
  • Additional basic infection control interventions (if necessary)

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Surgical patients with LOS>24h

Exclusion Criteria:

  • Surgical patients with LOS<24h
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00685867

Locations
Switzerland
Geneva University Hospitals
Geneva, Switzerland, 1211
Sponsors and Collaborators
University Hospital, Geneva
European Commission
  More Information

No publications provided

Responsible Party: Stephen Harbarth, Professor, University Hospital, Geneva
ClinicalTrials.gov Identifier: NCT00685867     History of Changes
Other Study ID Numbers: LSHP-CT-037940, LSHP-CT-037940
Study First Received: May 27, 2008
Last Updated: August 20, 2012
Health Authority: Switzerland: Swissmedic

Keywords provided by University Hospital, Geneva:
Staphylococcus aureus
Resistance
Prevention

Additional relevant MeSH terms:
Staphylococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections

ClinicalTrials.gov processed this record on April 14, 2014